Tenofovir + Levonorgestrel Vaginal Film
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Not Yet Determined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of Lagos
Details
- API: Tenofovir, Levonorgestrel
- Target: Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Cervical Mucus Changes
- Anti-Microbial
- Inactive Materials: Chitosan, Poly-Vinyl-Alcohol, Polyethylene Glycol
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: Developers indicate their intention to develop a self-administered, highly effective, biocompatible vaginal method.
Product Status
Active/Recent Pre-Clinical Development
History
2025: The University of Lagos publishes drug release and safety evaluation of a tenofovir + levonorgestrel vaginal film tested in rabbits. Their prototypes produced a favorable degradation time, cumulative release, and mucoadhesion score and histological analysis showed minimal irritation. Developers followed a Quality by Design development model intended to facilitate regulatory compliance and accelerate development.